Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up

Error message

Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

Leuven, BELGIUM, 10 April 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today communicates it has received an aggregate amount of EUR 450,000 in the framework of the Atlas Funding Program.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Wednesday, April 10, 2024

Information

Tags:

Eleventh, EUR, Brussels Stock Exchange, Atlas

Geotags:

HEVERLEE, BE

⚠ partially generated by AI ↴

Organisation:

OXURION, OXURION NV

Summary

Key Points:

Leuven, BELGIUM, 10 April 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today communicates it has received an aggregate amount of EUR 450,000 in the framework of the Atlas Funding Program.
On April 10, 2024, the Company issued the Eleventh Tranche consisting of 18 convertible bonds, for an aggregate amount of EUR 450,000.
This tranche has been issued in accordance with the agreement reached with Atlas end of 2023, as further described in the press release issued by the Company on December 28, 2023.

Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program
Eleventh tranche fully issued and paid-up

Leuven, BELGIUM, 10 April 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today communicates it has received an aggregate amount of EUR 450,000 in the framework of the Atlas Funding Program.

On April 10, 2024, the Company issued the Eleventh Tranche consisting of 18 convertible bonds, for an aggregate amount of EUR 450,000.

This tranche has been issued in accordance with the agreement reached with Atlas end of 2023, as further described in the press release issued by the Company on December 28, 2023.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

Please contact for additional information:

Oxurion NV
Pascal Ghoson
Chief Executive Officer
[email protected]

Backstage Communication
Jurgen Vluijmans
Partner
[email protected]

Attachments